FDA delays decision on Roche’s SMA drug to review extra dataThe FDA has extended its review of Roche’s spinal muscular atrophy (SMA) drug risdiplam after the pharma submitted Share XFDA delays decision on Roche’s SMA drug to review extra datahttps://pharmaphorum.com/news/fda-delays-decision-on-roches-sma-drug-to-review-extra-data/
EMA clears compassionate use of Gilead’s remdesivir for COVID-19The EU drugs regulator says Gilead Sciences’ antiviral drug remdesivir should be made available for people seriously ill Share XEMA clears compassionate use of Gilead’s remdesivir for COVID-19https://pharmaphorum.com/news/ema-clears-compassionate-use-of-gileads-remdesivir-for-covid-19/
AZ, GSK and Cambridge Uni will set up COVID-19 testing centreA new coronavirus diagnosis laboratory will be set up by AstraZeneca, GlaxoSmithKline and Cambridge University, as the UK Share XAZ, GSK and Cambridge Uni will set up COVID-19 testing centrehttps://pharmaphorum.com/news/az-gsk-and-cambridge-uni-will-set-up-covid-19-testing-centre/
Kids’ mental health app sees spike in users in COVID-19 crisisA mental health app for young people has seen a spike of 168% during the COVID-19 coronavirus outbreak Share XKids’ mental health app sees spike in users in COVID-19 crisishttps://pharmaphorum.com/news/kids-mental-health-app-sees-spike-in-users-in-covid-19-crisis/
Inovio begins clinical trial of COVID-19 vaccineUS-based Inovio has become the third biotech to begin clinical development of a vaccine against the COVID-19 coronavirus. Share XInovio begins clinical trial of COVID-19 vaccinehttps://pharmaphorum.com/news/inovio-begins-clinical-trial-of-covid-19-vaccine/
Cancer Research UK cuts research funding as COVID-19 hits incomeCancer Research UK has cut funding to its research activities, as the charity faces a cut to its Share XCancer Research UK cuts research funding as COVID-19 hits incomehttps://pharmaphorum.com/news/cancer-research-uk-cuts-funding-as-covid-19-hits-income/
Pharma bad boy Shkreli asks for prison release to fight COVID-19Pharma bad boy Martin Shkreli has asked authorities to let him out of prison, saying that he could Share XPharma bad boy Shkreli asks for prison release to fight COVID-19https://pharmaphorum.com/news/pharma-bad-boy-shkreli-asks-for-prison-release-to-fight-covid-19/
Plasma firms join forces on “unbranded” coronavirus treatmentA group of companies that specialise in plasma-derived drugs will pool their resources to try to develop a Share XPlasma firms join forces on “unbranded” coronavirus treatmenthttps://pharmaphorum.com/news/plasma-firms-join-forces-on-unbranded-coronavirus-treatment/
Oxford Uni spin-out Zegami seeks NHS X-rays for COVID-19 diagnosticA digital tool that could improve coronavirus diagnosis and guide treatment decisions has been developed by Oxford University Share XOxford Uni spin-out Zegami seeks NHS X-rays for COVID-19 diagnostichttps://pharmaphorum.com/news/oxford-uni-spin-out-zegami-seeks-nhs-x-rays-for-covid-19-diagnostic/
Hanover Health combines London public affairs and comms practicesHanover Health has restructured its London business, bringing its public affairs and communications practices together. The healthcare communications Share XHanover Health combines London public affairs and comms practiceshttps://pharmaphorum.com/news/hanover-health-alex-davies-emma-gorton/
Iceland’s Sidekick produces national COVID-19 patient trackerThe Iceland-based digital health company Sidekick has adapted its technology to provide remote monitoring, triage and support for Share XIceland’s Sidekick produces national COVID-19 patient trackerhttps://pharmaphorum.com/news/icelands-sidekick-produces-national-covid-19-patient-tracker/
Servier to acquire Danish cancer biotech SymphogenFrance’s Servier has signed a deal to buy the Danish biotech Symphogen, which specialises in antibody-based therapies for Share XServier to acquire Danish cancer biotech Symphogenhttps://pharmaphorum.com/news/servier-to-acquire-danish-biotech-symphogen/
GSK to collaborate with Chinese biotech on COVID-19 vaccineGlaxoSmithKline has announced plans to collaborate with China’s Xiamen Innovex on a potential vaccine to treat the COVID-19 Share XGSK to collaborate with Chinese biotech on COVID-19 vaccinehttps://pharmaphorum.com/news/gsk-to-collaborate-with-chinese-biotech-on-covid-19-vaccine/
US backs first emergency COVID-19 antibody test from CellexThe FDA has given its first approval to Cellex for a COVID-19 test that can detect whether someone Share XUS backs first emergency COVID-19 antibody test from Cellexhttps://pharmaphorum.com/news/us-backs-first-emergency-covid-19-antibody-test-from-cellex/
Apeiron starts mid-stage trial of drug that blocks coronavirusApeiron Biologics has been cleared to start a European phase 2 trial of a drug that it says Share XApeiron starts mid-stage trial of drug that blocks coronavirushttps://pharmaphorum.com/news/apeiron-starts-mid-stage-trial-of-drug-that-blocks-coronavirus/
Some pharmas acting like “toilet roll profiteers” on COVID-19, says clinicianA leading UK scientist says some drugmakers are acting like “supermarket hoarders” as coronavirus escalates, failing to share Share XSome pharmas acting like “toilet roll profiteers” on COVID-19, says clinicianhttps://pharmaphorum.com/news/some-pharmas-acting-like-toilet-roll-profiteers-on-covid-19-says-clinician/
GSK eyes nasal polyps use for Nucala after trial successGlaxoSmithKline is eyeing another indication for its Nucala (mepolizumab) biologic drug after a phase 3 trial in inflammation Share XGSK eyes nasal polyps use for Nucala after trial successhttps://pharmaphorum.com/news/gsk-eyes-nasal-polyps-use-for-nucala-after-trial-success/
Antitrust delay scuppers Novartis’ $1bn generics sale to AurobindoNovartis has called off the sale of two US generics businesses to India’s Aurobindo Pharma, part of a Share XAntitrust delay scuppers Novartis’ $1bn generics sale to Aurobindohttps://pharmaphorum.com/news/antitrust-delay-scuppers-novartis-1bn-generics-sale-to-aurobindo/
Key Questions To Boost Your KOL Management – Part 6/8: Engagement Plans Share XKey Questions To Boost Your KOL Management – Part 6/8: Engagement Planshttps://pharmaphorum.com/partner-content/key-questions-to-boost-your-kol-management-part-6-8-engagement-plans/
Novartis to speak at SMi Group’s Injectable Drug Delivery 2020 Share XNovartis to speak at SMi Group’s Injectable Drug Delivery 2020https://pharmaphorum.com/partner-content/novartis-to-speak-at-smi-groups-injectable-drug-delivery-2020/
PM Society Digital Awards 2020 – Entries Open! Share XPM Society Digital Awards 2020 – Entries Open!https://pharmaphorum.com/partner-content/pm-society-digital-awards-2020-entries-open/
PRISYM ID signals growth ambitions with appointment of new senior leadership team Share XPRISYM ID signals growth ambitions with appointment of new senior leadership teamhttps://pharmaphorum.com/partner-content/prisym-id-signals-growth-ambitions-with-appointment-of-new-senior-leadership-team/
Prescient hires senior members to Advisory Share XPrescient hires senior members to Advisoryhttps://pharmaphorum.com/partner-content/prescient-hires-senior-members-to-advisory/
Prescient Intelligence & Insight announces recent appointments to the senior team Share XPrescient Intelligence & Insight announces recent appointments to the senior teamhttps://pharmaphorum.com/partner-content/prescient-intelligence-insight-announces-recent-appointments-to-the-senior-team/
